Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Evaluating the long-term outcomes of low-dose radiation therapy for early-stage nodular lymphocyte-predominant Hodgkin lymphoma

Posted by on Jun 5, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of radiation, chemotherapy, or both for the treatment of early-stage nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL). This study concluded that long-term outcomes were favorable across all treatment approaches. Some background NLPHL is a rare subtype of non-Hodgkin's lymphoma....

Read More

Evaluating quality of life after pembrolizumab treatment for classical Hodgkin lymphoma

Posted by on Jun 5, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This phase 2 study evaluated the impact of pembrolizumab (Keytruda) on the quality of life of patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. This study concluded that the overall quality of life and health status was improved for these patients. Some background Most patients...

Read More

Evaluating brentuximab vedotin plus high-dose bendamustine for relapsed or unresponsive Hodgkin lymphoma

Posted by on May 31, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined how well brentuximab vedotin (Adcetris) plus high-dose bendamustine (Treanda) worked in patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL). This study concluded that this regimen was highly effective for these patients. Some background After initial treatment, many patients with cHL...

Read More

Evaluating PD-1 inhibitor therapy for recurrent or non-responsive classical Hodgkin lymphoma

Posted by on May 31, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This phase 2 study evaluated the effectiveness and safety of camrelizumab alone or in combination with decitabine (Dacogen) for recurrent or non-responsive classical Hodgkin’s lymphoma (cHL). This study concluded that the combined treatment was safe and highly effective in these patients. Some background Standard first-line...

Read More

Searching for patients with lymphoma or leukemia to test T-cell therapy after stem cell transplantation

Posted by on May 24, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This phase 2 trial is evaluating how well CD8+ memory T-cell therapy works in patients with leukemia or lymphoma after a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have full chimerism (donor cells work completely and only donor cells can be identified after transplant) after therapy. This...

Read More

Searching for children with advanced Hodgkin lymphoma to test a new chemoimmunotherapy combination regimen

Posted by on May 24, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study is evaluating the effectiveness of brentuximab vedotin (Adcetris) plus chemotherapy for children with advanced Hodgkin lymphoma (HL). The main outcome to be measured will be the number of patients who respond to treatment. The details Brentuximab vedotin is being tested to treat children who have advanced HL. Brentuximab...

Read More

PET scans in determining outcomes for patients with Hodgkin lymphoma treated with chemotherapy

Posted by on May 20, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the role of positron emission tomography (PET; an imaging technique) in determining the outcomes for patients with Hodgkin lymphoma treated with chemotherapy. This study concluded that negative-PET scans after chemotherapy predict good outcomes for these patients, regardless of stage at...

Read More

CRISPR

CRISPR

Posted by on May 1, 2019 in Blog, Hodgkin's lymphoma, Leukemia, Lymphoma, Non-Hodgkin lymphoma | 0 comments

Since the Human Genome Project published the first draft of the human genome in February 2001, there has been a boom in research and new technologies around genetics. The project revealed that humans have around 20,500 genes. Around 3 million base pairs make up these genes. CRISPR is a new technology that has arisen from this groundbreaking Human Genome...

Read More

Evaluating scoring systems used to predict outcomes for patients with advanced HL

Posted by on Apr 24, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of the International Prognostic Scoring System (IPSS) measuring 7 factors (IPSS7) versus the IPSS measuring 3 factors (IPSS3) in predicting outcomes for patients with Hodgkin's lymphoma (HL). This study concluded that there was no significant difference between these scoring systems. Some...

Read More

Searching for patients to try a new combination of treatments for relapsed or unresponsive Hodgkin lymphoma.

Posted by on Apr 22, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of pembrolizumab (Keytruda) and targeted radiation therapy for relapsed or unresponsive Hodgkin lymphoma (HL). This study will measure the rate of complete response (disappearance of all cancer). The details Many patients are cured with treatments for HL. Some patients lose response to...

Read More